Search
forLearn
5 / 801 resultslearn Tapyadi
learn tamsulosin
learn persimmon tannin
learn sulfur
Research
5 / 250 resultsresearch TARSAL CONTACT CHEMOSENSORY HAIRS OF THE LARGE WHITE BUTTERFLY PIERIS BRASSICAE AND THEIR POSSIBLE RÔLE IN OVIPOSITION BEHAVIOUR
B-type hairs on female butterfly legs help them choose where to lay eggs.
research Production and potential application of wood tar in dermatology and cosmetic
Wood tar could be useful for skin care in dermatology and cosmetics.
research The Noggin null mouse phenotype is strain dependent and haploinsufficiency leads to skeletal defects
Noggin gene inactivation causes skeletal defects in mice, varying by genetic background.
research Shampoo in the treatment of scalp psoriasis
Shampoos with specific ingredients are effective and safe for treating scalp psoriasis.
research Shampoo in the treatment of scalp psoriasis
Shampoos with specific ingredients are effective and safe for treating scalp psoriasis.
Community Join
5 / 1000+ resultscommunity Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US_Kintor Pharmaceutical Limited
Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.
community Kintors interim report from 9-2-24 for everyone whos interested
Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.
community GT20029. Kintor Pharma’s Product
The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.
community Anagenic is trying to compound Gt20029
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
community Kintor Pharma Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World’s First Topical Use PROTAC Compound
The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.